Sernova Corp., a regenerative medicine company, announces that Dr. Philip Toleikis, Sernova’s President and CEO, along with the additional Horizon 2020 HemAcure Consortium Leaders, will present an overview of key achievements in developing a novel cell-based therapy for the treatment of Hemophilia A, in a publicly accessible webinar.
The webinar will include an introduction to the consortium, an overview of bleeding disorders with a focus on Hemophilia A, the innovative therapeutic approach HemAcure is developing as well as results and achievements to date. Participants are welcome to submit their questions during the webinar through the Q&A section. Questions that are left unanswered due to time constraint will be collected and answered in a written follow-up published on the HemAcure website.
“Sernova is proud to be amongst the innovators participating in this product development program involving Sernova’s platform technologies with the goal to treat hemophilia A patients. HemAcure is another great opportunity for Sernova to collaborate with international experts to advance next-generation regenerative medicine therapies,” stated Dr. Philip Toleikis, President and CEO of Sernova.
Webinar: Results in Fighting Haemophilia A
Thursday October 25, 2018, 4:00 pm CEST (10:00 am ET)
Host: Dr. Gabriele Wagner (ARTTIC, Germany)
- Dr. Joris Braspenning (University Hospital Würzburg, Germany), Coordinator
- Prof. Dr. Antonia Follenzi (Università del Piemonte Orientale “Amedeo Avogadro,” Italy)
- Prof. Dr. Alexandra Stolzing (Loughborough University, UK)
- Dr. Philip Toleikis (Sernova Corp, Canada)
- Dipl.-Ing. Martin Zierau (Grünewald GmbH & Co. KG, Germany
The webinar will be made available on ARTTIC’s YouTube channel, HemAcure’s website and Sernova’s website shortly after the event.